- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01290172
Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.
A Single-center, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- University Hospital, Ghent
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability and willingness to provide written informed consent
- Cirrhotic patients with established clinically significant portal hypertension (CSPH) defined as an increase in hepatic venous pressure gradient >= 10 mmHg
- Recipients who are 18-70 years of age receiving a primary liver transplant from a brain dead donor or living donor
- Whole liver grafts and partial liver grafts can be included
Exclusion Criteria:
- Patients who are recipients of multiple solid organ transplants, or have previously received an organ or tissue transplant that may not be completely resolved by thrombectomy
- HIV positive patients
- Patients with known history of portal thrombosis or diagnosed at the time of transplantation that may not be completely resolved by thrombectomy.
- Patients included in the preoperative assessment without a CSPH at the time of the first intraoperative measurement of portal pressure
- Patients with low portal perfusion (=< 90 ml/min*100 g of LV) measured at the time of operation. Portal flows above this limit can be excluded in the eventuality that, after infusion, the portal perfusion falls below this limit
- Patients with porto-pulmonary hypertension
- Patients with known cardiac arrhythmias
- Recipients of cardiac-dead donors
- Fulminant hepatic failure patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Somatostatin
Patients in this group receive treatment with Somatostatin for 5 days.
|
6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg. 5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days. |
Placebo Comparator: Placebo
Patients in this group receive a placebo for 5 days.
|
The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg. 5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of safety and efficacy using Somatostatin.
Time Frame: 5 days
|
To evaluate the safety and efficacy, using Somatostatin as portal vein flow and pressure modulator in liver transplantation in humans.
Hepatic and systemic hemodynamic measurements will be recorded prior, during and after the bolus infusion of Somatostatin/Placebo during liver transplantation.
Infusion of Somatostatin/Placebo will be continued for 5 days.
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To elucidate pathophysiological pathways in non-cirrhotic grafted livers.
Time Frame: 35 days
|
35 days
|
To evaluate the reduction of ischemia-reperfusion injury (cytoprotective effect)
Time Frame: 1 hour after reperfusion and 5 days
|
1 hour after reperfusion and 5 days
|
To evaluate the efficacy of Somatostatin in the prevention of the small-for-size syndrome (SFSS) in partial liver transplantation.
Time Frame: after 35 days
|
after 35 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roberto Troisi, PhD, MD, University Hospital, Ghent
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008/689
- 2008-008319-24 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant With Clinically Significant Portal Hypertension
-
Centro Hospitalar De São João, E.P.E.CompletedClinically Significant Portal HypertensionPortugal
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPortal Hypertension | Clinically Significant Portal HypertensionUnited States
-
Yale UniversityOnyx Therapeutics, Inc.Completed
-
University Hospital, ToursHospices Civils de Lyon; Centre Hospitalier Universitaire Dijon; CHU de Reims; University... and other collaboratorsNot yet recruitingClinically Significant Portal Hypertension | Asymptomatic CirrhosisFrance
-
Loma Linda UniversityNational Institutes of Health (NIH)CompletedCancer Survivors With Clinically Significant DistressUnited States
-
Nantes University HospitalTerminatedCirrhotic Patient With Suspicion of Portal Hypertension and in a OV Screening ContextFrance
-
Meridian Bioscience, Inc.CompletedPatients With Compensated Liver CirrhosisUnited States, France, Switzerland, Spain
-
Assiut UniversityUnknownPredicting Liver Cell Failure & Portal Hypertension in LCEgypt
-
Shengjing HospitalRecruitingCirrhosis | Liver Portal HypertensionChina
-
University of MichiganCompletedLiver Disease | Portal HypertensionUnited States
Clinical Trials on Administration of Somatostatin
-
Fundació Institut de Recerca de l'Hospital de la...Unknown
-
Medical University of ViennaNot yet recruitingPancreatic Neuroendocrine Tumors in MEN1
-
University of MinnesotaCompletedType 1 Diabetes | Hypoglycemia UnawarenessUnited States
-
Australasian Gastro-Intestinal Trials GroupCanadian Cancer Trials GroupNot yet recruitingNeuroendocrine TumorsAustralia
-
UCB PharmaCompletedPeptic UlcerFrance, Poland, Spain, Belgium, Greece, Hungary
-
University of AarhusUnknownNeuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)Denmark
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
University of MinnesotaCompletedType 1 DiabetesUnited States
-
Hospices Civils de LyonActive, not recruiting
-
Mayo ClinicEnrolling by invitationPancreatic DiseasesUnited States